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DEFINITION AND CLINICAL PRESENTATION
In 1998, a WHO consensus conference defined urothelial cancers
and the preferred synomyn, urothelial cell carcinoma (UCC), in
place of transitional cell carcinoma (TCC) (Epstein et al, 1998).
Urothelial cell carcinoma accounts for up to 90% of malignant
bladder tumours in the United Kingdom. The remainder comprise
squamous cell carcinoma, adenocarcinoma and neuroendocrine
tumours. Mesenchymal tumours such as sarcoma and haemato-
logical-based ones such as lymphoma are rarely found in the
bladder, whereas adenocarcinoma from other pelvic organs
(prostate, ovary, endometrium and rectum) may on occasions
develop a true metastatic secondary lesion rather than problems
from direct extension.
Tumour grade is associated with tumour stage, disease
behaviour and prognosis. It has been traditionally defined G1–G3
by several systems based upon cell anaplasia and while this WHO
definition and those from 1979 and 1992 will have operated during
this period, separate systems were accepted by North America and
Scandinavia as well. As a result, comparison of outcomes by stage
has been problematic. In 1998, the WHO consensus classification
introduced the term ‘Papilloma of low malignant potential’,
equivalent to G1 (in Ta TCC the old WHO system), and low-
and high-grade papillary UCCs, equivalent to G2 and G3 TCC,
respectively. It was proposed that these terms would more closely
predict disease behaviour; however, their usage remains con-
troversial and will not have impacted on the period under study.
The TNM staging of bladder cancers is based on the depth of
invasion of the bladder wall (T), involvement of regional lymph
nodes (N) and the presence or absence of metastases (Sobin and
Wittekind, 2002).
Visible (macroscopic or frank) haematuria is the most common
presenting sign, occurring in approximately 75% of patients.
It is usually intermittent and painless. On investigation of male
patients at high risk (over 50 years) presenting with symptoms of
painless haematuria, between 20 and 25% are found to have
bladder cancer. A more difficult problem is presented with
invisible (microscopic) haematuria, which is associated with
bladder cancer in around 6% of men in cohort studies.
Unfortunately, 20% of male patients in the at-risk population are
found to have invisible haematuria from a variety of causes, and in
the same age group, up to 40% of women will have invisible
haematuria, demonstrating the large prevalence of invisible
haematuria (Khadra et al, 2000). Currently, there are no reliable
tumour markers for the detection of bladder cancer, and as a
consequence, all patients found to have significant invisible
haematuria are investigated to exclude cancer. Approximately
20% of patients do not present with either visible haematuria or
invisible haematuria but have irritative voiding symptoms such as
frequency and urgency. The persistence of these symptoms
following exclusion of a cause such as urinary tract infection
requires further assessment.
During the 20 years under study, significant advances have been
made in understanding the molecular pathology of TCC and the
differences in the way superficial and invasive tumours may arise
(Mitra et al, 2005). A number of genetic changes have been
identified but tumours with a low clinical risk for progression to
muscle-invasive disease show very little evidence of genetic
instability. In contrast, invasive tumours harbour many genetic
alterations (Kim and Quan, 2005; Wu, 2005; Knowles, 2006).
Mutations of the FGF receptor 3 in the absence of TP53 mutations
are frequent in low-grade papillary tumours. Deletions of
chromosome 9 are common in both invasive and non-invasive
cancers, and TP53 is the most frequently inactivated tumour
suppressor gene in invasive tumours. Recent evidence suggests
that oncogene-driven cell division cycles trigger the activation of
DNA-damage response in the early stages of tumorigenesis
(Bartkova et al, 2005).
Although the molecular events that characterise bladder cancer
are increasingly defined and our understanding of relevant
pathways and networks has evolved, it remains surprising that
no significant markers either for diagnosis of superficial or
invasive disease, let alone a marker able to define recurrence, or
relative prognosis have gained widespread acceptance and
consistent validity.
PATHOLOGY AND ITS RELATIONSHIP WITH
PROGNOSIS
The term superficial bladder cancer encompasses a spectrum of
disease that includes true superficial papillary lesions, which are of
relatively low clinical risk, as well as disease extending into the
lamina propria, which is at high risk of progressing to muscle-invasive
bladder cancer (MIBC). The majority of cancers at presentation
(70%) are confined to the urothelium (Ta) or have invaded
the sub-epithelial connective tissue of the lamina propria (T1). *Correspondence: P Whelan; E-mail: peter.whelan@leedsth.nhs.uk
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yet encompasses cancers that have low and high risk for
recurrence and progression and that have divergent molecular
pathways has resulted in a change of terminology from ‘superficial
bladder cancer’ to ‘non-muscle-invasive bladder cancer’ (NMIBC).
The term NMIBC more correctly describes the spectrum with its
diverse clinical and pathological phenotype.
A variant of NMIBC, carcinoma in situ, is most commonly seen
in association with either high-grade Ta, T1 lesions (20%), and in
MIBC. In approximately 5% of cases, carcinoma in situ occurs in
isolation (primary carcinoma in situ) and although this is not
invasive it behaves entirely differently from either Ta or T1 lesions,
with approximately 60% of patients developing invasive disease
over 5 years if left untreated.
TREATMENT OF NON-MUSCLE-INVASIVE
BLADDER CANCER
Bladder TCC is characterised by a tendency to recur in time and
space with a variable rate of progression. More than half of all
patients will experience recurrence, yet of these recurrences, only
10–15% will develop a subsequent muscle-invasive tumour and
therefore acquire a life-threatening disease.
A review in 1996 of combined EORTC and MRC randomised
clinical trials in superficial bladder cancer defined low-, inter-
mediate- and high-risk tumours and gave rise to consensus
guidelines for the surveillance and management of NMIBC
(Pawinski et al, 1996). In a more recent combined analysis of
2596 patients from seven EORTC trials, six clinical and
pathological factors, number of tumours, tumour size, prior
recurrence rate, T category, presence of carcinoma in situ and
tumour grade, were weighted to derive an algorithm for the
calculation of probabilities of recurrence and progression of
disease (available at http://www.eortc.be/tools/bladdercalculator)
(Sylvester et al, 2005).
Further development and validation of this algorithm is likely
before its widespread use; however, it highlights the need for such
a prognostic tool to individualise the outcome for bladder cancer
both in discussing prognosis with patients and as a potential
research tool for selecting patients for clinical trials. Furthermore,
it may be possible to evaluate and incorporate biomarkers into
future algorithms although to date no markers have shown robust
clinical utility in this setting.
Primary management of NMIBC involves endoscopic resection
of disease followed by intravesical adjuvant therapy. Perioperative
intravesical chemotherapy (mitomycin or epirubicin) is effective in
reducing tumour recurrence and is considered the standard of care
following tumour resection of NMIBC in Europe (NICE, 2002)
Prolonged administration of chemotherapy over 6 weeks achieves
a further benefit and is recommended for intermediate risk
disease. Unfortunately, chemotherapy alone has not been shown to
reduce progression and is considered insufficient for NMIBC,
which has high risk for recurrence and progression to muscle-
invasive disease.
Bacillus of Calmet and Guerin (BCG) is the standard therapy for
high-risk NMIBC; BCG delivered intravesically activates a den-
dritic cell T-helper cell inflammatory response resulting in the
infiltration of CD4, CD8 and natural killer cells. For optimal
response, BCG is given as a maintenance therapy out to 36 months
from diagnosis. A meta-analysis carried out in 2002 confirmed that
patients undergoing a maintenance regime had a reduction in the
risk of progression, although this effect was modest declining from
14% to a 10% risk (Sylvester et al, 2002). A later Cochrane
Collaboration review in 2005 comparing BCG with mitomycin-C
(an intravesical chemotherapeutic agent) confirmed that
BCG reduced recurrence in high-risk cancers but did not
demonstrate a definite benefit for progression or survival
compared with mitomycin-C (which has not been shown to
reduce progression).
TREATMENT OF MUSCLE-INVASIVE BLADDER
CANCER
Approximately 25% of new cases of bladder cancer are muscle-
invasive at presentation and up to 20% of initial NMIBC will
progress to muscle-invasive. At least 50% of these patients will
ultimately progress to metastatic disease. The standard treatment
remains radical cystectomy with overall 5-year survival up to 68
and 78% in patients with muscle
-invasive (pT2 and pT3a) and
lymph node-negative disease. Lymph node-positive disease is
associated with a significantly worse survival, present in approxi-
mately 25% of cases; the overall survival for patients with lymph
node-positive disease at 5 years is 25–30% (Stein et al, 2001).
Cystectomy is a complex procedure requiring urinary diversion
and is associated with perioperative complications in up to 30% of
patients and a mortality of 2.5% rising to 6% in the United
Kingdom. In the period under study, complex pelvic GU surgery
was undertaken in district hospitals and more recently there
has been a move towards specialist centres served by
multidisciplinary teams to manage MIBC. It is too early to
determine whether this shift in health-care delivery will have
impacted on survival; however, evidence that high-volume
specialist centres achieve improved outcomes would suggest that
future survival rates will improve. Radiotherapy is considered an
alternative to cystectomy and combined radiotherapy plus
chemotherapy shows promising results in MIBC, with 5-year
survival of 74% in selected series (Shipley et al, 2003). In the
United Kingdom, an analysis of crude data collected by the BAUS
Cancer Registry in 1999 showed no difference in apparent survival
or progression in the outcomes of T2 and early T3 disease treated
by surgery or radiotherapy (Whelan et al, 2002). Only in more
advanced T3 disease did surgery appear to have a greater survival
benefit but again this was on raw data and the problems of
understaging and occult pelvic node disease were not accounted
for in this comparison. Few randomised trials have been set up to
determine the effect of radiotherapy vs cystectomy in the
management of MIBC. The lack of quality evidence is the rationale
for the Cancer Research UK phase III trial of selective bladder
preservation vs radical cystectomy (SPARE) in patients with MIBC
(UKCRN, 2008).
In the middle of the period under review, effective chemother-
apy (methotrexate, vinblastine, adriamycin and cisplatin) against
invasive TCC was demonstrated for the first time (Sternberg et al,
1989). Subsequent global collaborative trials under the aegis of the
EORTC/MRC studied CMV, cisplatin, methotrexate and vinblas-
tine and established a 5% benefit for neoadjuvant chemotherapy
(Sternberg and Parmar, 2001). A more recent meta-analysis
confirmed the value of neoadjuvant chemotherapy as the standard
for muscle-invasive disease (ABC, 2005); however, its utility would
have been far too low to impact on survival in the years before
2001.
DISCUSSION
In the period under study, most treatments for NMIBC and MIBC
were delivered by district hospitals. Specialist centres were used
exclusively for the delivery of radiotherapy but the continuous
follow-up of these patients devolved back to district hospitals. The
development of cancer networks with centralised multidisciplinary
teams providing high-volume specialist care may change the
outcome for patients with MIBC. Within such centres, new
standards such as neoadjuvant chemotherapy, surgical teams with
high-volume expertise and intensive input to the operative and
perioperative management of radical cystectomy (Arumainayagam
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future.
During the second half of the period under study with a
doubling of the number of urological surgeons in England and
Wales, more streamlined methods for diagnosing patients with
haematuria – ‘The One Stop Haematuria Clinic’ – have been
developed for the detection of bladder cancer. The potential to
screen at-risk populations has not been realised in part because of
the high prevalence of invisible haematuria. It is possible that a
genomic risk stratification with incorporation of biomarkers will
be effective for the early detection of bladder cancer and there is a
need for research in this area in the future.
By far, the largest proportion of incident cases are NMIBC of
which high-risk disease will impact most on survival rates. A
consistent approach to registration of cases across the United
Kingdom will be important as misclassification of carcinoma
in situ and high-risk Ta has skewed survival data in the past,
making clinical correlation and international comparisons diffi-
cult. However, within the spectrum of NMIBC, the widespread
acceptance of maintenance BCG for high-risk disease has
engendered an awareness of aggressive entities within what was
termed superficial disease. Although there remains some doubt
about the absolute benefit of maintenance therapy, trials of novel
agents and delivery systems may begin to impact the outcome
for NMIBC. Finally, the consistently worst outcome of women
as reported in the survival data is not reflected in prospective
clinical trials. Deprivation factors may relate most closely
to smoking history and its potential effect on the evolution of
the cancer and its prognosis, as well as on increased levels of co-
morbidity. But more research is required to understand the causes
of the consistently worse outcome of women for survival.
CONCLUSION
The lack of change of survival in bladder cancer between the
late 1980s and 90s reflects the fact that standard approaches
to treatment for invasive bladder cancer remained largely
unchanged during that period. The use of chemotherapy in the
neoadjuvant, adjuvant and metastatic setting was both too
low and too patchy to make any major impact on survival.
It is hoped that more consistent and reproducible
pathological reporting, more timely use of surgery and
radiotherapy and the greater application of neoadjuvant and
adjuvant chemotherapy will, in this current decade, have begun
to make an impact.
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